We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Softens QbD Push in Final Guidance on Residual Drug in Transdermal Patches
FDA Softens QbD Push in Final Guidance on Residual Drug in Transdermal Patches
August 16, 2011
The FDA is easing back from its push of quality by design (QbD) as the sole way to minimize residual drug left in transdermal patches after their prescribed use.